Indian Journal of Urology
ORIGINAL ARTICLE
Year
: 2013  |  Volume : 29  |  Issue : 2  |  Page : 114--118

Living donor transplant options in end-stage renal disease patients with ABO incompatibility


Santosh S Waigankar1, Madhav H Kamat1, Shriram Joshi1, Bhupendra V Gandhi2, Madan Bahadur2, Rushi V Deshpande2 
1 Department of Urology and Renal Transplant, Jaslok Hospital and Research Centre, Mumbai, India
2 Department of Nephrology, Jaslok Hospital and Research Centre, Mumbai, India

Correspondence Address:
Shriram Joshi
Senior Consultant Urologist, Department of Urology and Renal Transplant, Jaslok Hospital and Research Centre, Mumbai, 15, Dr. Deshmukh Marg, Pedder Road, Mumbai- 400 026
India

Introduction: The options available to CKD 5 patients with donor shortage due to incompatibilities is to either get enlisted in cadaver transplant program or opt for three other alternatives viz; ABO-incompatible transplant (ABO-I), ABO-incompatible transplant with Rituximab (ABO-R) or paired-kidney exchange transplant (PKE). At our institute we have performed ABO-I, ABO-R and PKE transplants and we are presenting the results of these transplants performed at our institution. Here, we report our experiences of living donor kidney transplantation in highly sensitized patients. Objective: To review the options available to CKD 5 patients with incompatible donor. Materials and Methods: Between January 2008 and June 2011, 7 PKE, 26 ABO-I and 7 ABO-R transplants were carried out at our institute. Evaluation of both the recipients and donors involved biochemical, serological and radiological investigations. In case of PKE, recipients were operated simultaneously in different operation theaters. In ABO-I splenectomy was done while in ABO-R was given. Post-transplant the recipient management protocol remained the same. Expenditure following each transplant was calculated. Results: The graft and patient survival of ABO-I, ABO-R and PKE transplants 12-18 months after transplant were 78.9%:80%, 85.7%:85.7% and 100%:100%, respectively. Conclusions: The inclusion of Rituximab in the transplant protocol appears promising. The existing donor shortage could be addressed by encouraging other options like PKE. The limiting factor for ABO-R and PKE transplants is time and cost, respectively. The decision depends on the informed consent between the patient and the nephrologists.


How to cite this article:
Waigankar SS, Kamat MH, Joshi S, Gandhi BV, Bahadur M, Deshpande RV. Living donor transplant options in end-stage renal disease patients with ABO incompatibility.Indian J Urol 2013;29:114-118


How to cite this URL:
Waigankar SS, Kamat MH, Joshi S, Gandhi BV, Bahadur M, Deshpande RV. Living donor transplant options in end-stage renal disease patients with ABO incompatibility. Indian J Urol [serial online] 2013 [cited 2021 Apr 12 ];29:114-118
Available from: https://www.indianjurol.com/article.asp?issn=0970-1591;year=2013;volume=29;issue=2;spage=114;epage=118;aulast=Waigankar;type=0